IMMUNOHISTOCHEMICAL DEMONSTRATION OF PROSTATE-SPECIFIC ANTIGEN IN METASTASES WITH THE USE OF MONOCLONAL ANTIBODY-F5
- 1 January 1985
- journal article
- research article
- Vol. 121 (3) , 451-454
Abstract
With the use of a murine monoclonal antibody (F5), a panel of metastatic tumors was evaluated for the expression of prostate-specific antigen (PA) under immunoperoxidase staining procedures. Specimens studied included 25 of prostatic origin and 73 originating from nonprostatic primary sites. Regardless of the site of dissemination or the malignancy grade, all metastases from the prostate were antibody-reactive. In contrast, nonprostatic metastases were negative in each case, including those originating from other genitourinary neoplasms. Thus, PA expression as detected with monoclonal antibody F5 is a stable characteristic of disseminated prostatic tumors.This publication has 11 references indexed in Scilit:
- PURIFICATION OF A HUMAN PROSTATE SPECIFIC ANTIGEN1Journal of Urology, 2002
- PROGNOSTIC IMPORTANCE OF PROSTATE-SPECIFIC ANTIGEN FOR MONITORING PATIENTS WITH STAGE-B2 TO STAGE-D1 PROSTATE-CANCER1985
- Multiple Immunoperoxidase Markers in Benign Hyperplasia and Adenocarcinoma of the ProstateAmerican Journal of Clinical Pathology, 1984
- Immunohistologic Diagnosis of 2 Cases of Metastatic Prostate Cancer to BreastJournal of Urology, 1983
- Evaluation of Prostate Specific Acid Phosphatase and Prostate Specific Antigen in Identification of Prostatic CancerJournal of Urology, 1983
- Monoclonal Antibody (F5) to Human Prostate AntigenHybridoma, 1983
- Prostatic-specific antigen: An immunohistologic marker for prostatic neoplasmsCancer, 1981
- Prostate Antigen: A Marker for Human Prostate Epithelial Cells2JNCI Journal of the National Cancer Institute, 1981
- Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay.1980
- A PROSTATE ANTIGEN IN SERA OF PROSTATIC-CANCER PATIENTS1980